9,11-dihalogeno-4-pregnenes and 1,4-pregnadienes



the limitation of the manufacturing process.

United States Patent 9,11-DlI-IALOGENO-4-PREGNENES AND 1,4-PREGNADIENES David Gould, Leonia, Hans Reimann, Bloomfield, and Lawrence E. Finckenor, Lyndhurst, NJ assignors to Schering Corporation, Bloomfield, N.J., a corporation of New Jersey No Drawing. Application June 20, 1958 Serial No. 743,492

21 Claims. (Cl. 260397.45)

This invention relates to novel and therapeutically useful M-pregnenes and A -pregnadienes and to methods for their manufacture. In particular, this invention relates to 3,20-diketo-17u,2l-dihydroxy-9a,lIii-dihalogeno- 4-pregnenes, the corresponding 1,4-pregnadienes and 21- esters thereof; said compounds being valuable anti-inflammatory agents.

The new compounds prepared by the novel process of our invention described herein are members of the group consisting of pregnenes (I) and pregnadienes (II) of the following formulae:

I 11 wherein X is a halogen having an atomic weight greater than 19; Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X, and R is a member of the group consisting of hydrogen and acid radicals of the group consisting of lower alkanoic acids, dibasic organic acids having up to eight carbon atoms, and pharmaceutically acceptable polybasic inorganic acids. Also contemplated as falling within our invention are the Z-methyl, 60t-In6thyl, 16(oc or [3) -lower alkyl, and IGa-OR' analogs of the foregoing wherein R is a member of the group consisting of hydrogen and lower alkanoyl; and when R is hydrogen, the 160:,l7aacetonide, thereof.

Illustrative of the ill-esters contemplated above are lower alkanoates such as acetate, propionate, tertiarybutyl acetate, cyclopentylpropionate. Others prepared from dibasic organic acids are the succinate, phthalate, and the sulfobenzoates; and those from polybasic inorganic acids are sulfate, phosphate and the like.

As stated heretofore, the lip-halogen present in a compound of Formulae I or II, or an analog thereof, must be at least as electronegative as the halogen present in the 9a-position; fluorine being the most electronegative halogen, and iodine the least electronegative. Thus, a pregnene of pregnadiene of our invention containing a 9a-chloro-group may possess an 11 8-chloro or an 115- fluoro group but cannot contain an llfi-iodo or llfi-bromo group. This artificial restriction is imposed in view of Typical compounds of Formulae I and II and their analogs are: 90,1lfi-dichloro-4-pregnene-170:,21-diol-3,2O dione, 9abromo-l1B-fiuoro-4-pregnene-17a,2l-diol-3 ,20-dione, 90c, 11B-dich1oro-4-pregnene-l6a,l7a,21-triol-3,20-dione, 9a, 1lfl-dichloro-l6a-methyl-4-pregnene l7o,21 diol 3,20-

2,894,963 Patented July 14, 1959 "ice 2 diol-3,20-dione 21-acetate, 9a-bromo-1 1B-chloro-l,4-preg-' nadiene-17a,21-diol-3,20-dione and the Zl-acetate thereof, 90;,11,B-dichloro-1,4-pregnadiene 17oc,21 diol 3,20- dione, the Zl-acetate, 21-carbethoxylate, monosodium-o-sulfobenzoate thereof, 9a,ll;8-dichloro- 16B-methyl-1,4-pregnadiene-l70,21-di0l 3,20 dione, 9a,

The new 9,11-dihalogeno compounds of our inventionstrong anti-inflammafalling within Formulae I and II are are not salt-retaining.

tory agents which, advantageously,

That these compounds possess anti-inflammatory activity is in itself surprising in view of the fact that these compounds are dihalogeno derivatives of Reichsteins Compound S, an adrenal steroid of almost negligible pharmacological activity, and in view of the fact that never before has a steroid compound devoid of an oxygen at C-ll been found to possess any significant anti-inflammatory activity. Moreover, that our compounds are not salt-retaining is contrary to what might be expected in view of previous indications wherein the inclusion of a 9a-halogen in a steroid molecule is usually synonymous with imparting salt activity to the compound. Thus, in the case of prednisone and prednisolone, both widely used anti-arthritic steroids with negligible salt-retaining properties, the introduction of a 9a-fluoromoiety causes these compounds to become so salt-retaining as to render the 9oc-fl uoro-analog useless for anti-inflammatory therapy via oral or parenteral routes.

In treating anti-inflammatory disorders, our dihalogeno compounds exhibit greater activity and a longer duration of activity than prednisolone acetate while advantageously exhibiting negligible salt-retention. For example, 9a,-11fldichloro-17a,2l-dihydroxy-1,4-pregnadiene-3,20-dione is 20 times as active as prednisolone ZI-acetate when measured by the granuloma pouc'h test. Moreover, tests of the duration of eosinopenic activity reveal that, at equal doses, the Zl-acetate of the aforementioned dichloropregnadiene maintains of its initial activity two and a half times as long as does prednisolone acetate.

Our compounds are particularly valuable in human therapy when administered topically for the alleviation of inflammations and burns, and also in the treatment of atopic dermatitis (allergic eczema, food eczema, infantile eczema, nummular eczema, eczamatoid dermatitis, pruritis with lichenification, disseminated neurodermatitis), contact dermatitis due to plants (rhus poisoning) and other substances. When administered topically in humans, our compounds exhibit a greatly enhanced activity over other topical administerable steroids, and at the same time produce no systemic effects. This is unexpected of a halogen-containing-steroid in view of the systemic effects suffered by patients using ointments containing compounds such as 9a-fluorohydrocortisone. Our compounds have been found to be topically effective at smaller doses than used heretofore by other steroids, and, moreover, have been found to be effective in cases which do not respond to other corticosteroids. Topical preparations containing from 0.1 to 0.3% of one of our compounds are advantageously employed.

When administered intravenously in humans, our dihalogeno compounds elicit the effects commonly associated with corticoids. Thus, they are valuable therapeutics for such use in intravenous therapy as (1) acute adrenal crises, (2) acute surgical emergencies and (3) acute stressful situations. The parenteral compositions may and the '21- preferred em contain our therapeutically active compounds dissolved or suspended in such non-toxic liquid vehicles as diethylacetamide and saline or dextrose and saline. The dose may vary from to 25 milligrams depending upon the severity of the crises, and may be administered in one injection or by a slow-drip.

Our halogenated pregnenes and pregnadienes are also valuable therapeutic agents for veterinary use, particularly in smaller animals. For the treatment of ailments arising from inflammatory disorders in small animals, our compounds exhibit an activity several times that of prednisone and prednisolone; are much less catabolic than the latter compounds; and at the same time exhibit little or no salt retention. All the hormonal efiects such as thymus involution, liver weight increase, depression of circulating lymphocytes, and increase in polymorphonuclear leucocytes present in other anti-inflammatory steroids, such as cortisone, hydrocortisone, prednisone and prednisolone acetate, are present in our dihalogeno deriva tives if taken for long periods of time. However, the greatly enhanced activity of our compounds allows the use of such small doses, that these hormonal side effects are greatly minimized in our halogenated steroids. This combination of greatly enhanced anti-inflammatory activity, coupled with a minimum of salt retention and negligible undesirable hormonal side eifects, renders our dihalogeno-pregnenes and pregnadienes drugs of choice for use in dogs and other small animals for the alleviation of inflammatory conditions involving the joints and accessory tissues; certain skin conditions, such as non-specific dermatitis and summer or dry eczema, alleviation of stress conditions when used preor postoperatively, and as supportive therapy in traumatic shock. In animals, our compounds may be administered via all routes, i.e. orally, topically, subcutaneously, or intravenously. The dosage requirements are much less than those for other anti-inflammatory corticosteroids such as prednisone or prednisolone. Suggested dosages for small animals are in the range of 2-5 milligrams daily tapering down to a maintenance daily dose of 0.52.0 milligrams.

Our compounds (when used for dogs, for example) are administered orally in the form of tablets containing from 0.5 to 1 mgm. per tablet mixed with a solid carrier containing one or more of the usual excipients such as starch, sugar, gums, soaps, clays and the like. Where parenteral administration is indicated in animal treatment, subcutaneous or intramuscular injection of the substance dissolved or suspended in a suitable non-toxic liquid vehicle is preferred. Parenteral compositions preferably contain a 21-ester of the dihalogeno-pregnene or pregnadiene. Topical preparations containing O.l3% of active ingredient are advantageously employed.

Our dihalogeno compounds are prepared by reacting the corresponding 9,11-dehydro-4-pregnene or 9,1l-dehydro-1,4-pregnadiene with a halogen donor. Some of the 9,11-dehydro starting compounds are known, such as the 21-acetate of 4,9(1l)-pregnadiene-l7u,2l-diol-3,20- dione, the l-dehydro-analog thereof, and the 2l-acetate of 16a-acetoxy-4,9(11)pregnadiene-17a,2l-diol-3,20 dione. Other 4,9(ll)-pregnadienes may be prepared from the corresponding ll-hydroxylated 4-pregnenes by the action of reagents such as methanesulfonyl chloride in the presence of pyridine, phosphorous oxychloride in pyridine, or concentrated aqueous hydrochloric acid in refluxing benzene-ether. In the same way, 1,4,9(l1)-pregnatrienes starting compounds may be prepared from the corresponding ll-hydroxy-1,4-pregnadienes.

Halogen donors which may be used in our process are: (1) molecular halogens such as chlorine or bromine, (2) molecular halogen donors such as the addition compounds pyridinium bromide perbromide, dioxane dibromide, iodobenzene dichloride and p-iodotoluene dichloride, (3) a mixed halogen molecule such as iodine monochloride, (4) a mixture of reagents comprising a positive halogen donor such as a molecular halogen or a compound such 4 as N-chlorosuccinimide, N-bromoacetamide, dimethyl- N,N-dibromohydantoin, and N-iodosuccinimide, together with a halogen ion having an electronegativity equal to or greater than that of the above-mentioned positive halogen donor. Examples of such mixtures are lithium chloride and N-chlorosuccinimide, lithium chloride and chlorine, potassium fluoride and N-bromoacetamide, hydrogen bromide and N-bromoacetamide, potassium fluoride and N-iodosuccinimide, hydrogen chloride, lithium chloride and N-chlorosuccinimide, and the like. Whenever a mixture of halogen donor reagents are present in a reaction mixture, the more electronegative halogen attacks the ll-position. Thus, a compound reacted with potassium fluoride and N-iodosuccinimide will yield 9a-iodo- 1 1 fl-fluoro-derivatives.

The molecular halogens, molecular halogen donors, or mixed halogens, such as chlorine, bromine, iodobenzene dichloride, iodine monochloride, employed in our process may be used in their commercially available form, in which case they are added directly to the reaction mixture either alone or in a suitable solvent such as acetic acid or tetrahydrofuran. Alternatively, the desired ha1ogen or halogen mixture may be generated in situ by the addition of 0.9-1.2 equivalents, based on the amount of steroid, of a positive halogen donor, such as N-bromosuccinimide, to a reaction mixture containing a halogen ion of greater or equal electronegativity than the added halogen. This halogen anion may be supplied by a hydrohalic acid or a suitable salt such as sodium bromide, lithium chloride, potassium fluoride, or by mixtures of an acid and a corresponding salt. Whenever an acid is the source of halogen-anion, approximately theoretical quantities are generally used, whereas a salt-halogen-anion source may be present in large excess. Such an excess of anion is frequently useful when an increased yield or a purer compound is desired in a given reaction. A halogen-anion source may be used in reactions employing molecular halogens in which case an anion corresponding to the molecular halogen is used. A halogen-anion source may also be used in reactions which employ a mixed halogen, in which case a source of the more electronegative anion is used, i.e. a suitable chloride salt, or hydrochloric acid would be used in a reaction employing iodine monochloride.

It is apparent from the above, that there are a number of difierent ways in which the same compound may be prepared. For example, a 9a,11,8-dichloro-compound may be prepared by utilizing such reagents and combina tions as (1) chlorine and lithium chloride in acetic acid, (2) N-chloro succinimide and lithium chloride in glacial acetic acid, (3) sodium chloride and N-chlorosuccinimide in glacial acetic acid together with hydrogen chloride in tetrahydrofuran, (4) chlorine alone in glacial acetic acid, (5) chlorine and hydrogen chloride in glacial acetic acid, and (6) iodobenzene dichloride in acetic acid. The choice of solvent in each reaction is naturally determined by the solubility of the reagents in the process.

Our process, whereby a 9,11-dehydrosteroid is converted to a ,llp-dihalogeno-derivative is generally carried out in the presence of a suitable solvent at temperatures ranging from 5 C. to 50 C. for a period of from one-half hour to 24 hours, depending on the reagents involved. The preferred reaction conditions usually involve the use of glacial acetic acid as the sole or major solvent, with the reaction being carried out at room temperature for a period of approximately tWo hours.

Although glacial acetic acid is generally the preferred solvent, other solvents may be used in our dihalogenation process either alone or in combination with acetic acid. Solvents which may be employed include lower aliphatic acids such as acetic and diethylacetic, halogenated hydrocarbons such as methylene chloride and chloroform, satu rated ethers such as tetrahydrofuran and dioxane, other inert solvents such as dimethylsulfoxide; as well as suitable of these solvents.

When preparing the di-halogen-derivatives the reactive hydroxyl group at C-21 is preferably protected by prior esterification. Thus, the, 21-esters ofv the 4,9(11)pregnadienesor 1,4,9(11)-pregnatrienes are the preferred starting compounds. The 9a,11,6-dihalogeno-21-esters resulting from the process outlined above may then be conveniently saponified to the corresponding alcohols either chemically by the use of dilute acid or base, or microbiologically by procedures analogous to that described in South African Patent No. 3,462/55. Alternatively, a dihalogeno free alcohol prepared by our process, may be converted to an ester by the usual methods.

The compounds of our invention may be used either in the form of the free alcohol or as the ester derivatives of the 21-hydroxy1 group mentioned heretofore and including such as the acetate, propionate, isovalerate, enanthate, cyclopentylpropionate and tertiary butyl acetate. Other valuable 21-esters are the carbethoxylate, phenoxyacetate and substituted" phenoxyacetates such as the 4- choloro-, 2,4-dichloro, 4-bromo-, 4-methyl-, 4-tert.butyl, 2,4,5-trich1oro-, and 4-methoxyphenoxyacetates. The furoate and substituted furoates are also valuable esters.

The dihalogene-corticosteroids of our invention may also be used in the form of their water soluble derivatives, such as monosodium succinates, phthalates, sulfates, phosphates, glycinate salts, gluconates, monosodiumsulfobenzoates, and the like. The, following examples are illustrative of the procedures employed in preparing the compounds of this invention but are not to be construed as limiting the scope thereof, the scope of our invention being limited only by the appended claims.

EXAMPLE 1 9a bromo 11 8 chloro 1,4 pregnadiene 1701,21- dil-3,20-di0ne 21 -acetate 21-diol-3,20-dione 21-acetate; M.P. 190-195 C. (dec.); [12113 +172 (ioxane) 13, 5,9 239 my, e=14,500

Analysis.-Calcd. for C H O ClBr: C, 55.26; H, 5.65; Cl, 7.09; Br, 15.99. Found: C, 55.28; H, 5.34; Cl, 7.01; Br, 15.60.

EXAMPLE 2 90:,11/3 dichloro 1,4 pregnadiene 170;,21 dial 3,20- dione 21 -acetate A solution of 1.0 g. of 1,4,9(11)-pregnatriene-17u,2ldiol.-3,20-dione 21-acetate and 5.0 g. of lithium chloride in 40 ml. of glacial acetic acid is treated with 0.410 g. of N-chlorosuccinimide, followed by 0.104 g. of anhydrous hydrogen chloride dissolved in 2.5 ml. of tetrahydrofuran. The reaction mixture is stirred for 2 hours and poured into ice-water. The crude product is filtered and washed with water to give 1.12 g. of solid material, which is recrystallized from acetone-hexane to give substantially pure 90,1lp-dichloro-1,4-pregnadiene-17m21- diol-3,20-dione 21-acetate; M.P. 246-253 C. (dec.); [@1 +162 (dioxane) 1, 35? 237 mu, e= 15,000

Analysis.Calcd. for C H O Cl C, 60.66; H, 6.20;

Cl, 15.57. Found: C, 60.24; H, 6.14; Cl, 15.99.

The compound of this example is alternatively prepared by treating a solution of 1.0 g. of 1,4,9(11) -pregnatriene- 6 17u,21-diol-3,20-dione 21-a'cetate and 5.0 g. of lithium chloride in 40 ml. of glacial acetic acid with, a solution of 203- mg; of anhydrous chlorine in 5 ml. of tetrahydrofuran, followed by stirring at room temperature for 3 hours; work-up and physical constants as above.

EXAMPLE 3 904 bromo 11B 3 fluoro 1,4 pregnadiene 1711,21-

diol-3,20-di0ne 21 -acetate To a solution of 1.0 1g. of 1,4,9(11)-pregnatriene-17a, 21-diol-3',20-dione 21-acetate and 6.0 g. of potassium fluoride in a mixture of 40 ml. of diethyl acetic acid and 20 ml. of tetrahydrofuran is added 0.395 g. of N-bromoacetamide. The reaction mixture is stirred at room temperature for 20 hours, poured into ice-water, and extracted with methylene chloride. The extracts are washed in turn with sodium bicarbonate solution and water, followed by drying over anhydrous magnesium sulfate. The solvent is then evaporated to an oily residue which, on trituration with ether, gives 1.1 g. of the crude. product of this example. Chromatography on silica gel (100:1) and elution with 50% ether-hexane furnishes 9u-bromo-11fifluoro-1,4-pregnadiene-17a,21-diol-3,20-dione 21-acetate which isrecrystallized from acetone-hexane A l (32 239 my.

The compound of this example is alternatively prepared by treating 1,4,9 1 1 )-pregnatriene-17u,21-diol-3,20-dione 21-acetate with N-bromoacetamide in diethylacetic acid saturated with anhydrous hydrogen fluoride isolating and purifying the 9a-br0mo-1lfi-fiuoro-pregnadiene so obtained in the same manner as described above.

EXAMPLE 4 1,4,9(11 )-pregnatriene-1 7ot,21-diol-3,20-di0ne A solution of 2.0 g. of 1,4,9(11)-pregnatriene-17v,21- diol-3,20-dione 21-acetate in 100 ml. of a 3:1 methanolchloroform mixture is chilled in ice, to which is added dropwise 52 ml. of 0.1. N sodium hydroxide solution (1 equivalent). The reaction mixture is stirred at 0 C. for 10 minutes, then diluted with water and extracted with methylene chloride. Evaporation of the solvent and crystallization of the residue from acetone-hexane afiords 1,4,9(11)-pregnatriene-17u,21-diol-3,20-dione, M.P. 220- 228 C. (dec.)

1232 238 my, e=15,500

Analysis.-Ca1cd. for C H O C, 73.66; H, 7.66. Found: C, 73.58; H, 7.54.

EXAMPLE 5 9a,1Ifl-dichloro-l,4-pregnadiene-1 701,21 -diol-3,20-di0ne One gram of the compound of Example 4 is treated with chlorine gas and lithium chloride, in glacial acetic acid solution, as described in Example 2. The resulting. product is crystallized from acetone to give ;,11fl-dichloro-1,4-pregnadiene-17a,21-diol-3,20-dione; M.P. 238- 241 C. (dec.); [a] +134 (pyridine) A3 5? 237 my, e=15,400

Analysis-Calm. for C H O Cl C, 61.02; H, 6.34; Cl, 17.15. Found: C, 61.26; H, 6.30; C1, 16.66.

Alternatively the compound of this example is prepared by hydrolyzing the product of Example -2 according to the saponification procedure of Example 4. The crude product is crystallized from acetone; constants as above.

EXAMPLE 6 9a,11,8 dichloro 1,4 pregnadiene 17a,21 diol 3,20 dione 21-propionate To 1.0 g. of 9u,1lfi-dhcoloro-1,4-pregnadiene-17a,21- diol-3,20-di0ne prepared as in Example 5 there is added 1 ml. of propionic anhydride in 10 ml. of dry pyridine. The reaction mixture is left at room temperature for 3 '7 hours-then is poured with stirring into ice-water. The resulting precipitate is filtered, washed with water and crystallized from acetone-hexane to give 9u,llB-dichlord 1,4-pregnadiene-17a,21-diol-3,20-dione 2l-propionate,

max

EXAMPLE 7 9a,]1fi dichloro 1,4 prgenadiene 170:,12 dial- 3,20-dine 21 -carbeth0xylate 237 mp, .=14,s00

Analysis.Calcd. for C H O Cl C, 59.38; H, 6.23; l, 14.61. Found: C, 59.61; H, 6.29; Cl, 14.71.

EXAMPLE 8 9a,11p dichloro 1,4 pregnadiene 17%21 dial- 3,20-dione 21-sodium o-sulfobenzoate One gram of 9a,llfl-dichloro-1,4-pregnadiene-l7a,2'1- diol-3,20-dione, prepared as in Example 5, is dissolved in 25 m1. dry pyridine, then 445 mgm. o-sulfobenzoic anhydride is added. The reaction mixture is stirred overnight at room temperature, then poured into ice-water, acidified with cold dilute sulfuric acid, and extracted with methylene chloride. The combined organic extracts are evaporated to a residue which, after being dissolved in aqueous methanol, is brought to neutrality with dilute aqueous sodium hydroxide. The neutral solution is then distilled to dryness, and the resultant residue extracted with water. The aqueous extracts, in turn, are concentrated to a residue which is crystallized from acetonitrile-water to yield 9a,1lfi-dichloro-1,4-prcgnadiene- 17a,21-di01-3,20-dione 2l-sodium o-sulfobenzoate, M.P. 252254 C. (dec.);

X2332 235 my, e=15,000

EXAMPLE 9 fluoro 1,4 pregnadiene 170:,21-

9oz bromo 11/3 dial-3,20-di0r1e One gram of the 1,4,9(l l)-pregnatriene of Example 4 is reacted as described in Example 3 with N-bromoacetamide and potassium fluoride in diethylacetic acidtetrahydrofuran solution. Chromatography of the crude product on silica gel affords, on elution with ether, and crystallization from ethyl acetate-hexane, 9abromo-ll,8- fluoro-1,4-pregnadiene-17a,21-diol-3,20-dione;

A 239 mp EXAMPLE 90c bromo 11,8 fluoro 1,4 pregnadiene 1 7oz,'21- dial-3,20-dione 21 -dieflzyl acetate 8 EXAMPLE 11- 9oc chloro 11,8 fluoro 1,4 pregnadiene :,21-

dial-13,20-dione 21-acetate One gram of 1,4,9(-ll)-pregnatriene-l7u,21-diol-3,20- dione 2l-acetate is reacted wtih potassium fluoride in diethylacetic acid-tetrahydrofuran in the manner of Example 3, except that 400 mg. of N-chlorosuccinimide is used instead of the N-bromoacetamide The crude precipitate is chromatograp hed on silica gel. Elution with 50% hoxaneether, followed by crystallization from acetone,

90:,1113 dibromo 1,4 pregnadiene 1711,21 dial- 3,20--dione 21 -acetate To a solution of 1.0 g. of 1,4,9(ll)-pregnatriene-l7a, 21-diol-3,20-dione 2l-acetate in 40 ml. of methylene chloride there is added dropwise at 0 C. a solution of 420 mg. of bromine in 5 ml. of methylene chloride. The reaction mixture is stirred at 0 C. for 1 hour, then diluted with methylene chloride, washed with water, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual oil is dissolved in acetone, treated with decolorizing carbon and crystallized from acetone hexane, yielding 9051113 dibromo 1,4 pregnadiene-17a,21-diol-3,20-dione 2l-acetate; M.P. 142- 146 C. (dec.); [(11 (dioxane);

ALEQ 240 my, e=14,200

Analysis.-Calcd. for C H O Br C, 50.75; H, 5.18; Br, 29.37. Found: C, 51.00; H, 5.04; Br, 28.82.

The compound of this example is also obtained by treating a glacial acetic acid solution of 1,4,9(1l)-pregnatriene-l7a,2l-diol-3,20-dione 2l-acetate with N-bromoacetamide and hydrogen bromide.

EXAMPLE 13 9a ioa'o 11,6 chloro 1,4 pregnadiene 17u,21-di0l- 3,20-dione 21 -acetate The compound of this example is also prepared by the action of N-iodosuccinimide and lithium chloride, in acetic acid, on 1,4,9(11)-pregnatriene-17a,21-diol-3,20 dione 2l-acetate.

EXAMPLE 14 9a iodo 11/3 fluoro -l,4 pregnadiene 17a,21 dz'ol- 3,20-di0ne 21-acetate To a solution of 500 mg. of l,4,9(ll)-pregnatriene- 17a,'21-diol-3,20-dione 21-acetate and 3.0 g. of potassium fluoride in 40 ml. of dimethylsulfoxide there is added 300 mg. of N-iodosuccinimide. The reaction mixture is stirred at room temperature for 16 hours, poured into ice-water, and extracted with methylene. chloride. The organic extracts are then treated with decolorizing carbon, and concentrated in vacuo. The resultant residue is chromatographed on silica gel, the fraction eluted with 9 '5 ether-hexane yielding 9a-iodo-1lfl-fluoro-1,4-pregnadiene-17a,21-diol-3,20-dione 21-acetate;

ALfi 240 mp EXAMPLE 15 9a,]1B dichloro 4 pregnene 17a,21 diol 3,20- dione 21 -acetate A solution of 1.0 g. of 4,9(11)-pregnadiene-17a,21- diol-3,20-dione 2l-acetate and 5.0 g. of lithium chloride in 40 ml. of glacial acetic acid is treated with a solution of 200 mg. of chlorine gas in 3 ml. of tetrahydrofuran in the manner of Example 2. Crystallization of the crude product from acetone-hexane yields 9a,1lfi, dichloro-4-pregnene-'17a,21-diol-3,20-dione 21-acetate;

The corresponding 21-a1cohol is prepared from the 21-acetate of this example in the manner of Example 4, yielding 90,1lfi-dichloro-4-pregnene-l7a,21-dio1-3 ,20-d1- one.

EXAMPLE 16 9oc-brom0-11/8-flu0r0-4-pregnene-170:,21-di0l-3,20-di0ne 21 -acetate 9a,]LB-dichloro-4-pregnene-16a,1 7u,21-triol-3,20-di0ne 16a,21-diacetate Five grams of 4,9(11)-pregnadiene-16m,17a,21-triol- 3,20-di0ne 16a,21-diacetate are reacted with 1.5 grams of N-chlorosuccinimide in the manner of Example 2. The crude reaction product is crystallized from methanol to yield 9a,1lfi-dichloro-4apregnene-l6a,17a,2ltriol-3,20- dione 16a,2l-diacetate,

ALZB 240 111;;

EXAMPLE 18 1,4,9 11 -pregnatriene-16a,]7a,21-tri0l-3,20-dione 16a,21-diacetate Five grams of 1,4-pregnadiene-l1fi l6a,17a,21tetrol- 3,20-dione 16a,21-diacetate are dissolved in 20 ml. of dry dimethylformamide and 4 ml. of dry pyridine. The solution is chilled in an ice bath and to it is added dropwise 2.85 grams of methanesulfonylchloride which has been diluted to- 30 ml. with dimethylformamide. After the additionv has been completed, stirring is continued at room temperature for 48 hours. The reaction mixture is then poured into cold, dilute sulfuric acid, and the pre cipitated substance is filtered, air-dried, and crystallized from methanol to yield 1,4,9(11).-pregnatriene-16u,17a, 21-trio1-3,20-dione 16oc,21diacetate,

my 238 m EXAMPLE 19 9a -chl0r0-1lfl-fluoro-I,4-pregnadiene-16a,17a,21-tri0l- 3,20-di0ne 16,21-diacetate Five grams of 1,4,9.( l1)-pregnatriene 16u,17a,21 triol- 3,20-dione 16,21-diacetate, prepared as. described in Ex- '10 ample 18', is'reacted with 1.52 g. ofN-chloro-succinimide and 6 g. of potassium fluoride in the manner of Example 11.

The crude product is isolated, chromatographed, and crystallized from methylene chloride-hexane to give chloro llp-fluoro-l,4-pregnadiene-16a,17a,21-triol-3,20- dione 16,21-diacetate 7 7&5? 237 mp EXAMPLE 20 1-618-methyl-1,4,9 (11 )-pregnatriene-1 7a,21-di l-3,20- dione 21 acetate The requisite intermediate, 16,8-methy1-1,4-pregnadi- 8116-11,3,170c,21-tli013,20-di0116 21-acetate is prepared from 16-pregnene-3a-ol-11,20-dione 3-acetate in the manner described in co-pending application, Serial No. 673,141 of Richard Rausser et al., filed July 22, 1957.

16,8 methyl 1,4 -jpregnadiene-11(3,17u,2l-triol-3,20- dione 21-acetate (5 g.) is then reacted with methanesulfonyl chloride (3.05 g.), and the resultant crude product isolated in the manner described in Example 18. The crude product is then crystallized from methylene chloride-hexane to give l6p-methyl-1,4,9(11)-pregnatriene- 1'7 a,2l-diol-3,20-dione 21-acetate Mg? 238 my. EXAMPLE 21 9a,] 1 fl-dichloro-l 6/8-methyl-1 ,4 -pregnadiene-1 7oz,21 dial-3,20-dione ZI-acetate One gram of the l6;3-methyl-l,4,9(11)-pregnatriene prepared in above Example 20 is reacted with 0.34 gram of N-chloro-succinimide. in the manner of Example 2. The crude residue is isolated in the manner described and then crystallized from methanol to give 9a,11p-dichloro- 16B methyl-1,4-pregnadiene-l7a,2l-diol-3,20-dione 21- acetate The corresponding 21-alcohol of the 21-acetate of this example is prepared in the manner of Example 4, to give 911,115 dichloro-l6p-methyl-1,4-pregnadiene-17u,2l-diol- 3,20-dione.

EXAMPLE 22 One gram of 16p-methy1-1,4,9(l1)-pregnatriene-17a, 21-diol-3,20-dione 21-acetate prepared as in Example 20 is reacted with 0.34 g. of N-chloro succinimide and 6 g. of potassium fluoride in the manner described in Example 11. The crude product which is isolated is crystallized from methylenechloride to give 9oz-chloro-11B- fluoro-16fl methyl-1,4-pregnadiene-17u,21-diol3,20-dione 21-acetate EXAMPLE 23 6u-methyl-1,4,9(11 -pregnatrz'ene-1 7a,21 -di0l-3,20- dione 21 -acetate 60: methyl-1,4-pregnadiene-1lfi,l7a,21-trio1-3,20-dione ZI-acetate (5 g.) and methanesulfonyl chloride. (3.05 g.) are reacted in the manner of above Example 20 to yield a product which is crystallized from methanol to give 60c methyl-1,4,9 1 1)-pregnatriene-17a,2l-diol-3,20-dione 21-acetate M32 240 Ill .1.

EXAMPLE 24 9a,11fi-dichloro-6a-methyl-l,4-pregnaa'ieneJ 7a,21 -di0l- 3,20-di0ne 21-acetate 60c methyl 1,4,9(11) pregnatriene 17oc,21-di0l-3,20- dione 21-acetate (1 g.), prepared as in Example 23, and N-chlorosuccinimide (0.34 g.) are reacted in the manner of Example 2 to yield 9 ,1LB-dichloro-6u-methyl-L4-' pregnadiene-17a,21-diol-3,20-dione 21-acetate, which is crystallized from methylene chloride-ether max EXAMPLE 25 9a-chloro-I1fi-fluoro-6u-methyl-1,4-pregnadiene-I7a,21-

dial-3,20-dione 21 -acetate 60c methyl 1,4,9(11)-pregnatriene-17a,21-diol-3,20- dione 21-acetate (1 g.), prepared as in Example 23, is reacted with N-chlorosuccinimide (0.34 g.) and potassium fluoride (6 g.) in the manner of Example 11 to yield 90: chloro-llfi-fiuoro-M-methyl-1,4-pregnadiene-17u,21- diol-3,20-dione 21-acetate, which is crystallized from acetone-hexane EXAMPLE 26 2-methyl-4,9(]J )-pregnadiene-1 7a,21-diol-3,20-di0ne- 21 -acetate Five grams of 2-methylhydrocortisone 21-acetate is reacted with 3.05 grams of methanesulfonyl chloride in the manner described in Example 18. The crude product so obtained is crystallized from acetone-methanol to yield 2-methyl-4,9(11)-pregnadiene-17a,21-diol-3,20-dione 21- acetate EXAMPLE 27 2-methyl-9oz,1 1p-dichlora-4-pregnene-17a,2]-di0l-3,20- dione 21 -acetate 2 methyl-4,9(11)-pregnadiene-17u,21-diol-3,20-dione 2l-acetate (1 g.), prepared as in above Example 26, is reacted with N-chlorosuccinimide (0.34 g.) in the manner of Example 2. The crude product so obtained is crystallized from acetone-hexane to give 2-methyl-9a,11fldichloro-4-pregnene-17a,21-diol-3,20-dione 21-acetate xggs 238 my EXAMPLE 28 2-methyl-9a-chl0r0-1I/3-flu0r0-4-pregnene-170,21-diol- 3,20-dime 21 -acetate AQEE 238 mp The 21-acetate of this example is converted to the corresponding 21-a1cohol in the manner of Example 4, to yield 2-methyl-9a-chloro-1 1fi-fluoro-4-pregnene- 170:,21- diol-3,20-dione. 7

EXAMPLE 29 9a-bromo-1 lB-chloro-1,4-pregnadiene-17a,2l-diol-3,20- dione 2l-acetate, prepared as in Example 1, in 3:1 methanol-chloroform is hydrolyzed with 0.1 N-sodium hydroxide solution in the manner of Example 4 to give 90t-b1'01110-1 lfi-chloro-1,4-pregnadiene-17a,21-diol-3, 20-dione, [05113 +142 (pyridine);

RES 240 my, e=13,400

Analysis.-Calcd. for C H O BrCl: C, 55.09; H, 5.73; Cl, 7.74;-Br, 17.46. Found: C, 55.05; H, 5.89; CI. 7.88; 3. 1- a EXAMPLE 30 9a-br0mo-1 1 fi-ch loro-Z 6 we thyl-I ,4-pregnadiene-1 70:,21- dial-3,20-dione A. 16a-l\IETHYL-1,4,9 (11)-PREGNATRIENE-17a,21-DIOL 3,20-DIONE 21-ACETATE The requisite intermediate, 16ot-methyl-1,4-pregnadienc- 11,8,17u,21-triol-3,20-dione 21-acetate, is prepared from l6-pregnene-3u-ol-l1,20-dione in the manner described in copending application, Serial No. 733,843 of Richard Rausser et al., filed May 8, 1958.

l6a-methyl-1,4-pregnadiene-1 1B,17 x,21-tri0l-3 ,20-dione ZI-acetate (0.3 g.) is dissolved in 2 ml. of pyridine and there is added 0.1 ml. of methane-sulfonyl chloride in 2 ml. of pyridine. The solution is allowed to stand for five hours, then is poured into ice-hydrochloric acid. The solid which precipitates is filtered, washed with water, then recrystallized from acetone to give 16a-methyl- 1,4,9 1 l -pregnatriene-17a,21-diol-3,20-dione 21-acetate,

A52, 238 In (6 15,200) B. '9a,11fi-DICHLORO-1Sa-MIETHYL-lA-PREGNADIEND 17a,21-DIOL3,20-DIQNE ZI-ACETATE One gram of the 16ot-methyl-1,4,9(11)-pregnatriene, prepared as in above Example 30A, is reacted with 0.34 gram of N-chlorosuccinimide in the manner of Example 2 and the product isolated and purified in the described manner to give 9et,11,6-dichloro-16a-methyl- 1 ,4-pregnadiene-17o ,2l-diol-3,20-dione 21 -acetate.

C. 9a,11fl-DICHLORO-l6a-METHYL-1,4-PREGNADIENE- 17 a,21DIOL-3,20-DIONE A mixture of 0.5 g. of 9oc,llfl-dichloro-16u-methyl- 1,4-pregnadiene, 17a,21-di0l-3,20-di0ne 21-acetate, prepared as in above Example 303, in ml. of methanol, 20 ml. of chloroform, 5 ml. of water and 5 ml. of concentrated hydrochloric acid is allowed to stand 48 hours at room temperature. Water is then added, and the mixture extracted with methylene chloride. The organic extracts are washed with water, dried and concentrated to a residue. Crystallization of this residue from acetone yields 9ot,11;8-dichloro16a-methyI-L4-pregnadiene-17a,2l-diol-3,20-dione.

EXAMPLE 31 Qa-bromoJIB-chloro-Z6ot-ethyl-1,4-pregnadiene-17a,21- di0l-3,20dione A. 16a--E'lHYL-1,4,9 (11 -PREGNATRIENE17a,21-DIOL- 3,20-DIONE 21-ACETATE The requisite intermediate, 16ot-ethyl-1,4-pregnadiene- 11,8,17o,21-triol-3,20-dione 21-acetate, is prepared from l6-pregnene-3rx-ol-l1,20-dione in the manner described in copending application, Serial No. 733,843 of Richard Rausser et al., filed May 8, 1958.

16a-ethyl-1,4-pregnadiene-113,17a,21-triol 3,20 dione 21-acetate is reacted with methane-sulfonyl chloride in the manner described in Example 30A to give 16ot-ethyl- 1,4,9 1 1 -pregnatriene-17a,21-diol-3,20-dione 21-acetate.

B. 9a-BROMO-1 1 fi-CHLORO-16a-ETHYL-L4-PREGNADI- ENE-17a,21-DIOL-3,20-DIONE 21-ACETATE To a solution of one gram of the 16a-ethyl-1,4,9(11)- pregnatriene of above Example 31A and 5 grams of lithium chloride in 40 ml. of glacial acetic acid there is added 0.395 g. of N-b'romoacetarnide. The reaction mix ture is stirred at room temperature for two hours, then poured into ice-water. The mixture is filtered, and the precipitate washed with Water to yield 1.18 grams of the crude substance of this example. Recrystallization from acetone yields 9a-brorno-1lfi-chloro-l6a-ethyl-1,4-pregnadiene-17a,21-diol-3,20-dione 21-acetate.

C. Qa-BROMO-llfi-CHLORO-l6a-ETHYL-1,4-PREGNA- DlENE-17a,2l-DIOL-3,20-DIONE The 21-acetate of above Example 31B is hydrolyzed with methanol-chloroform-aqueous hydrochloric acid as described in Example 300, to yield 9a-bromo-l1p-chloro 16a-ethyl-1,4-pregnadiene-17a,21-diol-3,20-dione.

EXAMPLE 32 etate is reacted with methane-sulfonyl chloride in pyridine in the manner described in Example 30A to yield 1'6a-ethyl-4,9(l1')-pregnadiene-l7a,2l-diol-3 ,20-dione 21- acetate.

B. 9 11-11 fi-DICHLORO-l Ga-ETHYLA PREGNENE- 17a,21DIOL-3,20-DIONE 21-ACETATE 16a-ethyl-4,9(11)-pregnadiene-17a,21-dio1 3,20 dione 2l-acetate (5' g.) and p-iodotoluene dichloride. (4.2 g.) are dissolved in 100 ml. of methylene chloride. The solution is stirred for four hours at room temperature, then concentrated in vacuo to a residue which isrecrystalized from acetone-hexane to give 9u,1l,8-dichloro-l6aethyl-4-pregnene-l7a,2l-diol-3,20-dione 2l-acetate (4 g.). C. 9a,1lfi DICHLORO-l6a-ETHYL-4-PREGNENE- 17a,21-DIOL-3,20-DIONE The 2l-acetate of above Example 32B is hydrolyzed with methanol-chloroform-aqueous hydrochloric acid as described in Example 30C to yield 9a,11B-dichloro-l6uethyl-4-pregnene-17a,21-diol-3,20-dione.

EXAMPLE 33 9a,]1Brdichl0ro-4-pregnene-17a,21-di0l-3,20-di0ne 21-h emisuccinate 904,11 fl-dich1oro-4-pregnene-17a,21-dio1-3 ,20-dione (5 g.) prepared asin Example 15, is dissolved in pyridine (100 ml.) and succinic anhydride (5 g.) added. The. reaction mixture is stirred 20 hours at room temperature, then is diluted with ice water and acidified with cold, dilute sulfuric acid. The precipitate which forms is filtered, Washed with water, dried, and crystallized with acetonewater to yield 9a,llfi-dichloro-4-pregnene-l7a,21-diol-3- 20-dione 21-hemisuccinate.

A sample of the free acid-ester obtained above is then covered with Water and titrated to pH 7.1 with dilute sodium hydroxide. The solution is evaporated to a residue which is recrystallized from aqueous acetonitrile to give the sodium salt of 9u,11B-dichloro-4-pregene-l7a, 21-dio1-3,20-dione ZI-hemisuccinate.

EXAMPLE 34 9a,11 8-dichl0r0-1 ,4-pregnadiene-1 7a,21-di0l-3,20 dione 21 -hemisuccinate In the manner described in Example 33, 90,1lB-dichloro-1,4-pregnadiene-17a,2l-diol-3,20-dione, prepared as in Example 5, is reacted with succinic anhydride to give 90,1lfl-dichloro-lA-pregnadienel7a,2l-diol-3,20-dione 21-hemisuccinate.

The sodium salt of the above 1,4-pregnadiene hemisuccinate is prepared in the manner of Example 33.

'14 EXAMPLE 35 9bc,1l fi-dichloro-l ,4-pregnadiene-1 700,21-di0l-3,20- dione ZI-t-butylacetate 9a,1-1B-dichloro1,4pregnadienel7a,21-diol-3,20-dione (5 g.) prepared as in Example 5, is dissolved in 100 ml. of pyridine, the solution is cooled to below 10 C., and tertiary butylacetylchloride (1.5 g.) added. The mixture is stirred at room temperature for 16 hours, then poured into cold, dilute, sulfuric acid. The precipitate which forms is filtered, Washed with water, and crystallized from acetone to give ,llfi-dichloro-lA-pregnadi'ene-17u,2 l.-diol-3,20-dione 21-t-butylacetate.

EXAMPLE 36 9a,1lp-dichloro l,4-pregmldiene-1 700,21-di0l-3,20 dione 21 -phosphate A. 1,4,9'(11) -PREGNATRIENE-l7a,21-DIOL-3,20-DIONE ill-PHOSPHATE To'a solution of 1 gram of 1,4-prenadiene-1l/3,l7,2ltriol3,20-dione Ill-phosphate in 40 ml. of glacial acetic acid there is added, under an atmosphere of nitrogen, 8 ml. of 5.5 N-anhydrous hydrogen bromide. in glacial HCl dissolved in 2.5 m1. of tetrahydrofuran. The reacetic acid. The solution is allowed to stand at room temperature for twenty minutes and then is evaporated in vacuo to a residue substantially of l,4,9(ll)-pregna,- triene-17u,21diol-3,20-dione 21-phosphate which is used without further purification in the reaction immediately following.

B. 9a,11fl-DICHLORO-l'A-PREGNADIENE-17a,21-DIOL- 3,20-DIONE 21-PHOSPHATE One gram of the pregnatriene 21-phosphate of above Example 36A is dissolved in 40 ml. of glacial acetic acid and there is added 200 mg. of anhydrous chlorine in 5 m1. of tetrahydrofuran followed by mg. of anhydrous HCl dissolved in 2.5 ml. of tetrahydrofuran. The reaction mixture is stirred for 2 hours at 5-10 0., then is concentrated to dryness in vacuo at a temperature below 10 C., to. give, a residue substantially of 9a,1lB-dichloro- 1,4-pregnadiene-17ot,21-diol-3,20-dione 21-phosphate.

EXAMPLE 37 9a,]1B-dichl0r0-6a-methyl-1,4-pregnadiene-1 70:,21-

dial-3,20-dione CHaOR CH OR Wherein X is a halogen having an atomic weight greater than 19, Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X, R is a member of the group consisting of hydrogen and acid radicals of the group consisting of hydrocarbon monocarboxylic acids having up to 8 carbon atoms, dibasic organic acids having up to 8 carbon atoms, sulfate and phosphate, A and B are members of the group consisting of H and methyl and D is a member of the group consisting of H, u-lower alkyl, S-lower alkyl, ahydroxy and oz-IOWGI' alkanoyloxy, at least two of A, B and D being H.

2. The 21-acylates of 9a-X-11fi-Y-4-pregnene-17a,21- diol-3,20-dione, wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X, and the acyl group is that of a hydrocarbon monocarboxylic acid containing up to 8 carbon atoms.

3. 9a X 11B Y 1,4 pregnadiene 17a,2l diol- 3,20-dione wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X.

4. The 21-acylates of 9a-X-llfl-Y-lA-pregnadiene- 17a,21-diol-3,20-dione 'wherein X is a halogen having an atomic Weight greater than 19 and Y is a halogen having an atomic Weight less than 126 and being at least as electronegative as X, and the acyl group is that of a hydrocarbon monocarboxylic acid containing up to 8 carbon atoms.

5. The 21-hemiesters of 9oc-X-1 lfl-Y-lA-pregnadiene- 17a,21-diol-3,20-dione wherein X is a halogen having an atomic Weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X, and wherein the acyl component of the ester is an acid radical of a dibasic organic acid having up to eight carbon atoms.

6. 6oz methyl 90c X 11B Y l,4-pregnadiene-17a, 21-diol-3,20-dione, wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X.

7. The 21-acylates of 6a-methyl-9a-X-1lfi-Y-lA-pregnadiene-17a,21-diol-3,20-dione wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X, and the acyl group is that of a hydrocarbon monocarboxylic acid containing up to 8 carbon atoms.

8. 16-lower alkyl-9a-X-1lp-Y-4-pregnene-17a,2l-diol- 3,20-dione, wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic Weight less than 126 and being at least as electronegative as X.

9. The 21-acylates of 16-lower alkyl-9a-X-11fl-Y-4- pregnene-17a,2l-diol-2,20-dione, wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic weight less thanl26 and being at least as electronegative as X, and the acyl group is that of a "16 hydrocarbon monocarboxylic acid containing up to 8 carbon atoms.

10. 16-lower alkyl-9a-X-11,B-Y-1,4-pregnadiene-17a,21- diol-3,20-dione, wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at least as electronegative as X.

11. The 21-acylates of 16-lower alkyl-9a-X-11fl-Y-L4- pregnadiene-17u,2-diol-3,20-dione, wherein X is a halogen having an atomic weight greater than 19 and Y is a halogen having an atomic Weight less than 126 and being at least as electronegative as X, and the acyl group is that of a hydrocarbon monocarboxylic acid containing up to 8 carbon atoms.

12. The 16,21-diacylates of 9a-X-II S-Y-L4-pregnadiene-16a,17a,21-triol-3,20-dione, wherein X is a halogen having an atomic Weight greater than 19 and Y is a halogen having an atomic weight less than 126 and being at lease as electronegative as X, and the acyl group is that of a hydrocarbon monocarboxylic acid containing up to 8 carbon atoms.

13. 904,113 dichloro 1,4 pregnadiene 17u,2l diol- 3,20-dione.

14. 911,115 dichloro 1,4 pregnadiene 17u,2l diol- 3,20-dione 21-acetate.

15. :,115 dichloro 1,4 pregnadiene 1711,21 diol- 3,20-dione 21-phosphate.

16. 90:,11fi dichloro 1,4 pregnadiene l7a,2l diol- 3,20-dione 21-hemisuccinate.

17. 90:,11/9 dichloro 1,4 pregnadiene 1711,21 diol- 3,20-dione Zl-carbethoxylate.

18. 6oz methyl 90:,115 dichloro 1,4 pregnadiene- 17u,21-diol-3,20-dione.

19. 16a methyl 9a,11 8 dichloro 1,4 pregnadiene- 17a,21-diol-3,20-dione.

, 20. 16B methyl 9a,11 8 dichloro 1,4 pregnadiene- 17a,2l-diol-3,20-dione.

21. 9a,11;8 dichloro 4 pregnene 17a,21-diOl-3,ZO- dione 21-acetate.

References Cited in the file of this patent UNITED STATES PATENTS 2,387,706 Reichstein Oct. 23, 1945 2,401,775 Reichstein June 11, 1946 2,409,798 Reichstein Oct. 22, 1946 2,837,515 Chemerda et a1. June 3, 1958 2,865,935 Schneider et a1. Dec. 22, 1958 OTHER REFERENCES Handbook of Chemistry and Physics, 35th edition (Cleveland: Chemical Rubber Pub. Co., 1953), page 369 necessary. 

1. COMPOUNDS OF THE GROUP CONSISTING OF 17A,21-DIHYDROXY-3,20-DIKETO-9,11-DIHALOGENO PREGNENES AND PREGNADIENES HAVING THE FOLLOWING RESPECTIVE FORMULAE: 